Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

Anti-CD38 CAR NK-cells: an off-the shelf therapy for multiple myeloma

Michael O’Dwyer • 17 May 2019
Multiple Myeloma Antibodies NK-Cell Therapy

Michael O’Dwyer, MD, PhD, National University of Ireland, Galway, Ireland, discusses how anti-CD38 CAR NK-cells could selectively target myeloma cells to minimize off-target toxicity. This video was recorded at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from Michael O’Dwyer

ST3GAL1 as a novel biomarker of lack of sustained MRD negativity in multiple myeloma
8:47
ST3GAL1 as a novel biomarker of lack of sustained MRD negativity in multiple myeloma
Michael O’Dwyer • 12 Dec 2024
Genomic and transcriptomic analysis of R/R myeloma in the Phase III BELLINI study
3:31
Genomic and transcriptomic analysis of R/R myeloma in the Phase III BELLINI study
Michael O’Dwyer • 30 Nov 2020
Current myeloma cellular therapy landscape and horizon scan
5:14
Current myeloma cellular therapy landscape and horizon scan
Michael O’Dwyer • 30 Nov 2020
Cellular therapy: NK-cells as a model
2:01
Cellular therapy: NK-cells as a model
Michael O’Dwyer • 21 May 2020

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Michael O’Dwyer • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Michael O’Dwyer • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Michael O’Dwyer • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Michael O’Dwyer • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals